Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605553 | 0.86 | FFAR1 (0.52) | MAPTMEN1KMT2ATP53NPC1 | |
| SCHEMBL30795764 | 0.83 | HPGD (0.55) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL3089726 | 0.82 | MEN1 (0.60) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL3106451 | 0.80 | RAB9A (0.52) | MEN1KMT2ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4469453 | 0.80 | ALDH1A1 (0.51) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL3106692 | 0.77 | MAPT (0.51) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL3101950 | 0.76 | MAPT (0.49) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL10750131 | 0.76 | MEN1 (0.83) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL10746702 | 0.75 | MEN1 (0.71) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL11253322 | 0.75 | MAPT (0.65) | MAPTMEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | claimed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | claimed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | claimed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | disclosed |
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| US-7601870-B2 | Such as Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; potassium channel modulators; epilepsy | H. LUNDBECK A/S (DK) | 2009-10-13 | — | — | US | disclosed |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | disclosed |
| EP-1983974-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | disclosed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | KCNQ4, KCNQ5, KCNQ1 | MAPT 1786/4885MEN1 4004/4885KMT2A 309/4885 |
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | NDUFS3, NAT1, PRMT3 | MAPT 2817/4885MEN1 1540/4885KMT2A 398/4885 |
| US-20060155121-A1 | Substituted aniline derivatives | UGT2B7, NAT1, CYP1A2 | MAPT 1406/4885MEN1 806/4885KMT2A 1829/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | MAPT 1260/4885MEN1 1693/4885KMT2A 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.